Dan Skovronsky
Dr. Dan Skovronsky is the Chief Scientific Officer at Eli Lilly, where he has played a pivotal role in the development of innovative treatments for diabetes and obesity. Recently, he announced promising results from clinical trials of orforglipron, an experimental GLP-1 pill that significantly helped participants with type 2 diabetes lose weight and lower blood sugar levels.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Estonia | 1 | 8.00 | 0.09% | +0% | 1,326,539 | 1,193 | $31,000 | 28$ |
| Totals | 1 | 1,326,539 | 1,193 | $31,000 | 28$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Estonia:
Eli Lilly's chief scientific officer Dan Skovronsky mentioned that the new medication could be a primary treatment for both type 2 diabetes and obesity.
8
United States:
Dr. Dan Skovronsky, Lilly’s chief scientific officer, said in April that his company has begun mass-producing orforglipron pills after previous promising results.
8
United States:
Dr. Dan Skovronsky, Lilly’s chief scientific officer, expressed confidence in the trial results before they were released.
8